Education
About Us
Working with TipRanks
Follow Us
Longeveron (LGVN)
NASDAQ:LGVN
LGVN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.77 - $6.40
Previous CloseN/A
Volume215.49K
Average Volume (3M)253.25K
Market Cap
$21.61M
Enterprise Value$5.26M
Total Cash (Recent Filing)$10.50M
Total Debt (Recent Filing)$2.60M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
May 09, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.05
Shares Outstanding13,473,898
10 Day Avg. Volume138,984
30 Day Avg. Volume253,246
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.54
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.79
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$8.67Price Target Upside502.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial MilestoneThe ELPIS II trial of laromestrocel has achieved over 90% enrollment and, if positive, could facilitate a Biologics License Application submission.
Market PositionLaromestrocel is expected to have an advantage due to an absence of the amyloid-related imaging abnormalities (ARIA) side-effects that have affected currently approved anti-amyloid drugs.
Regulatory ProgressThe FDA agreed to consider a Biologics License Application (BLA) based on positive interim trial results from the planned single study, which is considered a particularly positive sign.
Bears Say
Operational RiskRisks include failure of Lomecel-B in the ELPIS-II trial of hypoplastic left heart syndrome patients and inability to obtain regulatory approval.
Regulatory RiskRisks include failure of Lomecel-B in the ELPIS-II trial of HLHS patients and inability to obtain regulatory approval for Lomecel-B in HLHS.
---
Ownership Overview
13.47% Insiders
1.94% Mutual Funds
0.42% Other Institutional Investors
83.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LGVN FAQ
What was Longeveron’s price range in the past 12 months?
Longeveron lowest stock price was $0.77 and its highest was $6.40 in the past 12 months.
What is Longeveron’s market cap?
Longeveron’s market cap is $21.61M.
When is Longeveron’s upcoming earnings report date?
Longeveron’s upcoming earnings report date is May 09, 2025 which is in 23 days.
How were Longeveron’s earnings last quarter?
Longeveron released its earnings results on Feb 28, 2025. The company reported -$0.434 earnings per share for the quarter, missing the consensus estimate of -$0.37 by -$0.064.
Is Longeveron overvalued?
According to Wall Street analysts Longeveron’s price is currently Undervalued.
Does Longeveron pay dividends?
Longeveron does not currently pay dividends.
What is Longeveron’s EPS estimate?
Longeveron’s EPS estimate is -0.33.
How many shares outstanding does Longeveron have?
Longeveron has 13,473,898 shares outstanding.
What happened to Longeveron’s price movement after its last earnings report?
Longeveron reported an EPS of -$0.434 in its last earnings report, missing expectations of -$0.37. Following the earnings report the stock price went down -9.211%.
Which hedge fund is a major shareholder of Longeveron?
Currently, no hedge funds are holding shares in LGVN
---
Company Description
Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
---
LGVN Company Deck
---
LGVN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of Longeveron's progress, with strong revenue growth and regulatory advancements highlighted. However, challenges like enrollment delays in clinical trials and anticipated increases in future expenses were also noted. The call reflected cautious optimism about Lomecel-B's potential, supported by robust clinical data and regulatory designations, though future financial and strategic uncertainties remain.Read More>---
LGVN Stock 12 Month Forecast
Average Price Target
$8.67
▲(502.08% Upside)
Technical Analysis
Mesoblast
―
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering LGVN
1 Year
1 Year Success Rate
1/15 ratings generated profit
1 Year Average Return
-66.83%
reiterated a buy rating 26 days ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 6.67% of your transactions generating a profit, with an average return of -66.83% per trade.
---